… of MJFF’s Patient Council and the FIRE-UP PD Steering Committee. Michael S. Fitts (MF): You’re the executive director of the CARE Research Center at Massachusetts General Hospital. CARE stands for … trials. We recognize the only way to do that is to try to address the problem at its source. We do a lot of …

… grant: Structural Characterization of the GCase/LIMP-2 Complex Promising Outcomes of Original Grant: Our original … (GCase) and its transporter LIMP-2. About seven to 12 percent of Parkinson’s patients carry mutations in the … compartment important for cellular waste removal. In previous work, we found that LIMP-2 can increase GCase …

… Genia Brin is thoughtful, soft-spoken and not given to hyperbole. When asked about her son and daughter-in-law’s … and Anne (Wojcicki, co-founder of personal genetics company 23andMe), a Silicon Valley power couple doing … of Parkinson’s patients worldwide. Double your impact now! Visit michaeljfox.org/challenge .   Lauren Shoor …

… Study Rationale: Research studies have yet to clearly explain whether alpha-synuclein oligomers -- … many possible reasons for this lack of clarity, extensive testing of new critical raw materials, such as monoclonal … and tested according to regulatory guidance for future commercialization as a companion diagnostic, i.e., a test …

… Amantadine is currently the only available medication to treat levodopa-induced dyskinesia: involuntary, jerky … varied duration of efficacy. Therefore, an alternative or complementary treatment is sought. A compound called fenobam showed an effect on dyskinesia in pre-clinical models. This study will test the effects of …

… the use of stem cells for treating Parkinson’s, we wanted to provide an update on this closely watched area of … to explore and develop recipes for coaxing stem cells to become dopamine-producing neurons that could potentially be … benefits. Clinical trials are mostly in early stages to test their safety and efficacy, and results so far involve …